Four Food and Drug Administration draft guidance documents and the REGROW Act: A litmus test for future changes in human cell- and tissue-based products regulatory policy in the United States?
Open Access
- 21 May 2018
- journal article
- review article
- Published by Wiley in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 12 (7) , 1579-1593
Abstract
Modern regenerative medicine research has expanded well past the development of traditional drugs and medical devices with many promising new therapies encompassing an increasingly diverse range of substances, notably cell-based therapies. These substantial recent developments and the progress in the health care and therapeutics fields necessitate a new regulatory framework agile enough to accommodate these unique therapies and acknowledge their differences with traditional pharmaceuticals. In the United States, recent proposed changes in the regulatory framework for autologous human cells, tissues, and cellular and tissue-based products (HCT/Ps) and their perceived risk-benefit analysis for patients remain controversial in the scientific field. To provide perspective on of the current status of the most recent attempts to redefine and conceptualize these changes in the United States, we will examine 4 draft guidance documents implemented by the Food and Drug Administration in interpreting relevant concepts and terminology pertaining to HCT/Ps: the Bipartisan Policy Center think tank report, "Advancing Regenerative Cellular Therapy: Medical Innovation for Healthier Americans," the proposed REGROW Act for HCT/Ps, and the current 24 Food and Drug Administration-approved HCT/Ps and related products in the United States.Keywords
This publication has 17 references indexed in Scilit:
- Expedited approval system for regenerative medicine products - Is it unusual?Regenerative Therapy, 2016
- Stem the tideNature, 2015
- Corrigendum to “Surface stress-based biosensors” [Biosens. Bioelectron. 51 (2014) 124–135]Biosensors and Bioelectronics, 2015
- Regulatory approval for autologous human cells and tissue products in the United States, the European Union, and JapanRegenerative Therapy, 2015
- New Japanese Initiatives on Stem Cell TherapiesCell Stem Cell, 2015
- New Governmental Regulatory System for Stem Cell—Based Therapies in JapanTherapeutic Innovation & Regulatory Science, 2014
- Are Differences in Disability-Free Life Expectancy by Gender, Race, and Education Widening at Older Ages?Population Research and Policy Review, 2014
- The regulation of allogeneic human cells and tissue products as biomaterialsBiomaterials, 2013
- The productivity crisis in pharmaceutical R&DNature Reviews Drug Discovery, 2011
- Lessons from 60 years of pharmaceutical innovationNature Reviews Drug Discovery, 2009